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Abstract
Introduction Oestrogens can mediate some of their cell survival
properties through a nongenomic mechanism that involves the
mitogen-activated protein kinase (MAPK) pathway. The
mechanism of this rapid signalling and its dependence on a
membrane bound oestrogen receptor (ER), however, remains
controversial. The role of G-protein-coupled receptor and
epidermal growth factor (EGF) receptor in an ER-independent
signalling pathway modulated by oestrogen was investigated.
Methods ER-positive and ER-negative breast cancer cell lines
(MCF-7 and SKBR3) and primary breast cancer cell cultures
were used in this study. Cell proliferation was assessed using
standard MTT assays. Protein and cAMP levels were detected
by Western blotting and ELISA, respectively. Antigen
localization was performed by immunocytochemistry,
immunohistochemistry and immunofluorescence. Protein
knockdown was achieved using small interfering RNA
technologies.
Results EGF and oestrogen, alone and in combination, induced
cell proliferation and phosphorylation of MAPK proteins Raf and
ERK (extracellular signal regulated kinase)1/2 in both ER-
negative SKBR3 and ER-positive MCF-7 human breast cancer
cell lines. Increased Raf phosphorylation was also observed in
primary human breast cultures derived from ER-positive and ER-
negative breast tumours. Oestrogen induced an increase in
intracellular cAMP in ER-negative SKBR3 human breast cancer
cells. Oestrogen-mediated cell growth and phosphorylation of
MAPK was modified by the EGF receptor antagonist AG1478,
the G-protein antagonist pertussis toxin, and the angiotensin II
receptor antagonist saralasin. Knockdown of angiotensin II type
1 receptor (AT1) protein expression with small interfering RNA
attenuated oestrogen-induced Raf phosphorylation in ER-
negative cells. AT1 receptor was found to be expressed in the
cell membrane of breast tumour epithelial cells.
Conclusion These findings provide evidence that, in breast
cancer cells, oestrogen can signal through AT1 to activate early
cell survival mechanisms in an ER-independent manner.
Introduction
Oestrogens induce diverse physiological effects that allow
normal development and growth of female reproductive tis-
sues, and regulation of bone integrity, cardiovascular function
and the central nervous system. Aberrant expression of oestro-
gen can induce pathophysiological effects that give rise to the
growth of tumours, in particular those of the breast. Classi-
cally, the mechanism of action of oestrogen was singularly
attributed to the binding of nuclear oestrogen receptor (ER)
and subsequently activation of target genes over the course of
several hours. More recently, it has become clear that oestro-
gen may rapidly act on cells in seconds to minutes, implicating
a nongenomic mechanism of oestrogen signalling.
In addition to its ability to promote ER-dependent gene tran-
scription, oestrogen rapidly triggers a variety of second mes-
senger signalling events, including mobilization of intracellular
calcium [1-3], production of cAMP [4,5], generation of inositol
triphosphate [6], and activation of mitogen-activated protein
kinase (MAPK) [7-9], phosphatidylinositol 3-OH kinase and
AKT/protein kinase B [10-12]. Nongenomic effects of oestro-
gen purportedly result from the steroid binding a receptor pro-
tein in the cell membrane [13].
AT1 = angiotensin II type 1 receptor; EGF = epidermal growth factor; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; ERK = 
extracellular signal-regulated kinase; GPCR = G-protein-coupled receptor; MAPK = mitogen-activated protein kinase; siRNA = small interfering RNA.Breast Cancer Research    Vol 8 No 3    Lim et al.
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Membrane ERs have been shown to exist in discrete caveolar
domains in the plasma membrane [14,15]. Studies in CHO
cells have identified similarly sized nuclear and membrane ER
proteins that result from the expression of a single cDNA [16].
Membrane ER is thought to be G-protein linked, with oestro-
gen binding resulting in activation of many signal transduction
pathways that emanate from G protein activation (for extensive
review, see [17]). It was recently reported that the E-domain of
membrane ER is required for activation of the MAPK cascade
[15] and that serine at amino acid 522 is necessary for the
translocation of ER-α to the plasma membrane [18]. In breast
cancer cells plasma ER is thought to exist as functional dimers
when bound by a steroid ligand [19], but oestrogen-depend-
ent endothelial nitric oxide synthase activation in ER-trans-
fected COS cells may not require dimerization [20].
Studies using ER-negative cell lines suggest that oestrogen
may also function in an ER-independent manner. Studies from
several laboratories have demonstrated that, in ER-negative
cells, oestrogen can signal through the G-protein-coupled
receptor (GPCR) GPR30 to transactivate epidermal growth
factor receptor (EGFR) and activate the MAPK cascade
[21,22]. This oestrogen transactivation of EGFR has been
shown to be via the release of surface-associated heparin-
binding epidermal growth factor [23]. It has been demon-
strated that this GPR30-dependent oestrogen induction of
MAPK is transient and under the control of a cAMP-dependent
negative feedback loop.
Data from the above studies suggest that oestrogen can initi-
ate rapid MAPK signalling in an ER-dependent and ER-inde-
pendent manner. First, oestrogen can bind a membrane ER,
similar or identical to the nuclear receptor, and subsequently
activate G proteins; secondly, oestrogen can also directly acti-
vate GPCR in the membrane in an ER-independent manner,
thereby effecting G protein activation.
More than one GPCR may participate in rapid oestrogen sig-
nalling, and it is likely that further complexity in oestrogen-
mediated GPCR signalling may occur as a result of coupling
of different G protein heterodimers with the same receptor.
Angiotensin II receptor is of particular interest as a candidate,
oestrogen-interacting GPCR. Inwang and colleagues [24]
demonstrated expression of angiotensin II type 1 (AT1) recep-
tors in both normal and diseased human breast tissues. Other
studies showed that activation of AT1 receptor stimulates
growth factor pathways such as tyrosine kinase phosphoryla-
tion and induces an increase in phospholipase C, leading to
activation of downstream proteins such as MAPK [25], Janus
kinases and STAT (signal transducers and activators of tran-
scription) proteins [26]. More recently, a study by Greco and
colleagues [27] conducted in MCF-7 cells and primary breast
cancer cells revealed that AT1 receptor regulates mitogenic
signalling pathways by two simultaneous mechanisms, one
involving protein kinase C and the other EGFR transactivation
[27].
We conducted the present study to investigate a combined
rapid oestrogen and epidermal growth factor (EGF) activation
of the MAPK cascade in both ER-positive and ER-negative
breast cancer cells. We describe a role for AT1 in mediating
this nongenomic oestrogen-signalling pathway.
Materials and methods
Cell lines and primary cell cultures
Human breast cancer cell lines MCF-7 (ER-positive) and
SKBR3 (ER-negative) were obtained from American Type Cul-
ture Collection (Rockville, MD, USA) and cultured in RPMI
1640 medium (Sigma Ltd, Ireland), enriched with 5% foetal
bovine serum (Sigma Ltd) and supplemented with the antibiot-
ics penicillin (100 ng/ml) and streptomycin (100 ng/ml; Invit-
rogen Ltd, UK) and amphotericin B (2 µg/ml; Invitrogen Ltd,
Paisley, UK).
Primary cell cultures derived from histologically confirmed ER-
positive and ER-negative breast primary tumours were pre-
pared as previously described [28]. In brief, following ethical
approval breast tumour specimens were obtained from
patients undergoing surgery for removal of a histologically
confirmed breast tumour. Primary tumour epithelial cells were
extracted in Hanks' balanced salt solution without calcium or
magnesium (Gibco, Paisley, Scotland) supplemented with 1
µmol/l EDTA and 1 µmol/l DTT for 40 minutes. Cells were cul-
tured in RPMI containing 5 µg/ml insulin, 10 µg/ml transferrin,
30 nmol/l sodium selinate, 10 nmol/l hydrocortisone, 10 nmol/
l oestradiol, 10 mmol/l Hepes, 2 mmol/l glutamine, 10% foetal
calf serum (weight/vol) and 5% ultroser G on a growth factor
reduced matrigel matrix (60 ng/cm2; BD Biosciences, San
Jose, CA). Cell viability and epithelial origin of tumour cells
were confirmed as previously described [28].
Human breast cancer cells were incubated in a humidified
atmosphere of 5% carbon dioxide at 37°C. Experiments were
carried out when the cells reached 90% confluence and fol-
lowing 24 hours incubation in serum-free medium without phe-
nol red. Where indicated, cells were preincubated with
receptor antagonists 60 minutes before addition of EGF
(Sigma) and/or 17 µ-oestradiol (10-8 mol/l; Sigma). EGFRs
were inhibited with tyrophostin AG1478 (150 nmol/l), GCPRs
with pertussis toxin (50 ng/ml), and angioteinsin II receptors
with saralasin A2275 (1 µmol/l; Sigma).
MTT thiozolyl blue proliferation assay
Cell proliferation was measured using MTT thiazolyl blue
assay. Approximately 1,000 cells were seeded in each well of
a 96-well plate, cultured, serum starved without phenol red
and treated as above. Then, 5 mg/ml MTT (Sigma) in 1:10 dilu-
tion per well was added and incubated for 3–4 hours. TheAvailable online http://breast-cancer-research.com/content/8/3/R33
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Figure 1
Effect of 17β-oestradiol and EGF on cell proliferation and induction of MAPK protein expression in breast cancer cells Effect of 17β-oestradiol and EGF on cell proliferation and induction of MAPK protein expression in breast cancer cells. (a) Cell proliferation findings. 
SKBR3 and MCF-7 human breast cancer cells, and ER-negative and ER-positive primary breast cultures derived from patient tumours were treated 
with EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination for 24 hours. Cell proliferation assays were carried out using MTT thio-
zolyl blue. Proliferative index of the control group is standardised to 1. The results shown are expressed as mean ± standard error (n = 9). Statistical 
analysis was performed using Mann Whitney U test (*P < 0.02 versus control). (b) Western blot analysis of phospho-Raf and total Raf protein 
expression. SKBR3 and MCF-7 human breast cancer cells, and ER-negative and ER-positive primary breast cultures derived from patient tumours 
were treated with EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination for 10 minutes. (c) Phospo-ERK1/2 and total ERK1/2 
protein expression. SKBR3 and MCF-7 human breast cancer cells were treated with 5, 10 and 50 ng/ml EGF and 17β-oestradiol (10-8 mol/l) alone 
and in combination for 10 minutes. Results are representative of those obtained in three separate experiments. (d) Immunocytochemical localisation 
of phospho-ERK in ER-negative SKBR3 cells treated with EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination for 30 minutes. 
The slides were counter stained with Mayer's haematoxylin solution and viewed under a light microscope at 200× magnification. Positive cells 
stained cells stained brown against a blue background. Results are representative of those obtained in three separate experiments. E2, 17β-oestra-
diol; EGF, epidermal growth factor; ER, oestrogen receptor; ERK, extracellular signal regulated kinase; MAPK, mitogen-activated protein kinase; PI, 
proliferative index.Breast Cancer Research    Vol 8 No 3    Lim et al.
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cells were lysed by adding 200 µl/well of dimethyl sulfoxide
(Sigma Ltd) and read at 570 nm absorbance wavelength in a
microtitre plate spectrophotometer.
Western blot analysis
Samples containing 50 µg protein were electrophoresed on
12% SDS polyacrylamide gels (Bio-Rad Laboratories Ltd,
Hertfordshire, UK) and transferred onto a nitrocellulose mem-
brane. The membranes were probed with the phospho-Raf,
phospho-ERK (extracellular signal regulated kinase)1/2
(1:1000; Cell Signalling), Raf, ERK1/2 and AT1 (1 µg/ml;
Santa Cruz, CA, USA) followed by the corresponding horse-
radish peroxidase-conjugated mouse or rabbit secondary anti-
bodies (Amersham Biosciences, Buckinghamshire, UK).
Chemiluminescence detections were carried out using Lumi-
Figure 2
17β-estradiol and EGF induced cell proliferation and raf phosphorylation is mediated through EGFR 17β-estradiol and EGF induced cell proliferation and raf phosphorylation is mediated through EGFR. (a) SKBR3 and MCF-7 breast cancer cells 
were pretreated with or without the EGFR antagonist AG1478 (150 nmol/l) 1 hour before treatment with EGF (10 ng/ml) and 17β-oestradiol (10-8 
mol/l) alone and in combination for 24 hours. Cell proliferation assays were carried out using MTT thiozolyl blue. Proliferative index of the control 
group is standardized to 1. The results shown are expressed as mean ± standard error (n = 9). Statistical analysis was performed using Mann-Whit-
ney U test (*P < 0.02 versus without AG1478). (b) Western blot analysis of phospho-Raf and total Raf in SKBR3 and MCF-7 breast cancer cells 
pretreated with or without the EGFR antagonist AG1478 (150 nmol/l) for 1 hour before 10 minutes of incubation with EGF (10 ng/ml) and 17β-
oestradiol (10-8 mol/l) alone and in combination. Results are representative of those obtained in three separate experiments. E2, 17β-oestradiol; 
EGFR, epidermal growth factor receptor; PI, proliferative index.Available online http://breast-cancer-research.com/content/8/3/R33
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Figure 3
Effect of GPCR antagonism on 17β-oestradiol and EGF induced cell proliferation, Raf phosphorylation and cAMP production in breast cancer cells Effect of GPCR antagonism on 17β-oestradiol and EGF induced cell proliferation, Raf phosphorylation and cAMP production in breast cancer cells. 
(a) SKBR3 and MCF-7 breast cancer cells pretreated with or without the GPCR antagonist PTX (50 ng/ml) 1 hour before 24 hours of incubation 
EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination. Cell proliferation assays were carried out using MTT thiozolyl blue. Prolif-
erative index of the control group is standardized to 1. The results shown are expressed as mean ± standard error (n = 9). Statistical analysis was 
performed using Mann Whitney U test (*P < 0.02 versus without PTX). (b) Western blot analysis of phospho-Raf and total Raf in SKBR3 and MCF-
7 cells pretreated with or without the GPCR antagonist pertussis toxin (50 ng/ml) for 1 hour before 10 minutes of incubation with EGF (10 ng/ml) 
and 17β-oestradiol (10-8 mol/l) alone and in combination. Results are representative of those obtained in three separate experiments. (c) Intracellular 
cAMP levels in SKBR3 cells treated with EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination. Results are expressed as mean 
± standard error (n = 9). Statistical analysis was performed using Mann-Whitney U test (*P < 0.02 versus control). E2, 17β-oestradiol; EGFR, epi-
dermal growth factor receptor; GPCR, G-protein-coupled receptor; PI, proliferative index.Breast Cancer Research    Vol 8 No 3    Lim et al.
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nol (Santa Cruz) or enhanced chemiluminescence with Super-
Signal (Pierce, Rockford, IL, USA).
cAMP ELISAs
Concentrations of cAMP were measured using cAMP enzyme
immunoassay in accordance with the manufacturer's protocol
(Sigma-Aldrich Ireland Ltd, Dublin, Ireland). The assays were
performed in a 96-well plate coated with anti-rabbit IgG anti-
body. The coloured end products, produced by addition of
substrate to the wells, were read at 405 nm absorbance wave-
length on a multiwell plate reader. The intensity of the colour
was inversely proportional to the concentration of cAMP
present in the well.
Immunodetection/microscopy
Immunodetection was carried out on fixed SKBR3 breast can-
cer cells and primary breast cancer tissue. Immunocytochem-
istry and immunohistochemistry were used to detect phospho-
ERK1/2 and AT1 on fixed cells and on paraffin-embedded tis-
sue, respectively. SKBR3 cells were cultured on 8-well cham-
ber slides (Lab Tek, Campbell, CA, USA) and subsequently
fixed and permeabilized. For tissue, 5 µm sections were cut
from paraffin-embedded breast tumour blocks and mounted
on slides. Sections were dewaxed and rehydrated. Antigen
retrieval was performed by immersing section in 0.6 mol/l cit-
rate buffer and microwaving on high for 7 minutes. Endog-
enous peroxidase activity was blocked in fixed cells and
tumour sections with 3% hydrogen peroxide for 20 minutes.
Antigens were detected using the Vectastain Elite kit (Vectra
Labs, Burlingame, CA, USA) in accordance with the manufac-
turer's instructions. Briefly, cells and sections were blocked in
serum for 90 minutes. Cells and sections were incubated with
primary antibodies, mouse anti-human phospho-ERK 1/2
[1:400]; New England Biolabs, Ipswitch, MA, USA) or rabbit
anti-human AT1 receptor (2 µg/ml; Santa Cruz) for 60 minutes
at room temperature. Subsequently, sections were incubated
in the corresponding biotin-labelled secondary antibody (1 in
2000) for 30 minutes, followed by peroxidase-labelled avidin
biotin complex. Sections were developed in 3,3-diaminobenzi-
dine tetrahydrochloride and counterstained with haematoxylin.
Negative controls were performed using matched IgG con-
trols (Dako, Glostrup, Denmark). Sections were examined
under a light microscope.
Immunofluorescence detection of AT1 was performed on
SKBR3 cells and primary breast cancer tissue. Cells and tis-
sue were prepared as described above. Breast cancer cells
and sections were blocked in 1.5% normal serum and then
incubated with 20 µg/ml rabbit anti-human AT1 in 10% human
serum for 90 minutes. Cells and sections were subsequently
incubated with Alexa Fluor 594-conjugated secondary anti-
body (Molecular Probes, Paisley, UK) for 60 minutes and were
counterstained with DAPI (Sigma-Aldrich). Confocal micros-
copy was performed using a confocal microscope (model
MRC 1024; Bio-Rad Laboratories, Hertfordshire, UK) and
images were captured using Laser Capture software (Zeiss
LSM 510 UV META system, Carl Zeiss Ltd., Hertfordshire,
UK).
Small interfering RNA transfection
Small interfering RNAs (siRNAs) predesigned by Ambion
(Austin, TX, USA) were used. The siRNA sequences targeting
AT1 (AT1 #1 [AGTR1 siRNA ID:1988], 5'-GGCCCUAAA-
GAAGGCUUAUtt-3' [NM_000685]; AT1 #2 [AGTR1 siRNA
ID:2083], 5'-GGCUUAUGAAAUUCAGAAGtt-3'
[NM_000685]) were assessed for their ability to downregu-
late AT1 protein expression. Silencer Negative Control #1
(scrambled) siRNA or Silencer®  GAPDH siRNA (Human;
Ambion) were used in accordance with the manufacturer's
instructions as control siRNA. SKBR3 cells were transfected
using a Nucleofector (Amaxa Biosystems, Cologne, Ger-
many). Cells were transfected with 1.5 µg siRNA in Nucleofec-
tor solution V using programme A-23. Immediately following
tranfection RPMI was added to the SKBR3 cells, which were
then plated in 6-well tissue culture plates overnight. Cells were
collected the following day and analyzed for protein expres-
sion by Western blotting.
Statistical analysis
The strengths of associations between the various parameters
measured during this study were tested using nonparametric
tests, which do not assume that data are normally distributed.
Mann-Whitney U test was used to compare two independent
groups of sampled data, analyzed by Statview® statistical pro-
gram (SAS, Cary, NC, USA). Two-sided P values below 0.05
were considered statistically significant. Data are expressed
as mean ± standard error of the mean.
Results
17β-Oestradiol and EGF alone and in combination 
induced breast cancer cell proliferation and rapid 
activation of the MAPK pathway
Both 17β-oestradiol and EGF induced cell proliferation in ER-
negative SKBR3 cells and ER-positive MCF-7 cells (Figure
1a). In SKBR3 cells, combined treatment with 17β-oestradiol
and EGF induced a further increase in cell proliferation
compared with either treatment alone. To examine the effect of
17β-oestradiol and growth factor treatment on MAPK activa-
tion, we examined their ability to induce phosphorylation of Raf
and ERK1/2. In ER-positive and ER-negative breast cancer
cell lines and in primary cell cultures derived from patient
tumours, both 17β-oestradiol and EGF increased expression
of phospho-Raf and phospho-ERK1/2 (Figure 1b, c). Com-
bined treatment with steroid and growth factors resulted in a
further increase in phosphorylation of the MAPK proteins. The
ability of 17β-oestradiol and EGF to mobilize ERK1/2 was also
examined. Increased nuclear localization of phospho-ERK1/2
was observed in the presence of EGF and in particular in the
presence of 17β-oestradiol and 17β-oestradiol in combination
with EGF (Figure 1d).Available online http://breast-cancer-research.com/content/8/3/R33
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Figure 4
The role of the AT1 receptor in 17β-oestradiol and EGF-mediated cell proliferation and Raf phosphorylation in breast cancer cells The role of the AT1 receptor in 17β-oestradiol and EGF-mediated cell proliferation and Raf phosphorylation in breast cancer cells. (a) SKBR3 and 
MCF-7 breast cancer cells pretreated with or without angiotensin II receptor antagonist saralasin (10-6 mol/l) 1 hour before 24 hours of incubation 
with EGF (10 ng/ml) and 17β-oestradiol (10-8 mol/l) alone and in combination. Cell proliferation assays were carried out using MTT thiozolyl blue. 
Proliferative index of the control group is standardized to 1. The results shown are expressed as mean ± standard error (n = 9). Statistical analysis 
was performed using Mann-Whitney U test (*P < 0.02 versus without saralasin). (b) Western blot analysis of phospho-Raf and total Raf in SKBR3 
cells pretreated with or without the AT1 antagonist saralasin (10-6 mol/l) for 1 hour before 10 minutes of incubation with EGF (10 ng/ml) and 17β-
oestradiol (10-8 mol/l) alone and in combination. Results are representative of those obtained in three separate experiments. (c) Western bolt analy-
sis of AT1 and phospho-Raf in SKRB3 cells transiently transfected with GAPDH siRNA, scrambled siRNA, or AT1 (#1 or #2) siRNA before treat-
ment with 17β-oestradiol (10-8 mol/l) for 10 minutes. Results are representative of those obtained in three separate experiments. Optical density 
readings of control values were normalized to 1 and experimental groups were expressed as a ratio. Values are expressed as mean ± standard error 
(n = 3). (d) Immunohistochemistry was carried out for AT1 receptor on primary human breast cancer tissue (7 µm). Negative control was matched 
IgG. The slides were counterstained with Mayer's haematoxylin solution and were viewed under a light microscope at 40× and 200× magnifications. 
Positive cells stained cells stained brown against a blue background. (e) Immunofluorescence studies of AT1 receptor in human primary tumour 
breast cancer tissue (7 µm) and SKBR3 breast cancer cells. Slides were viewed under a confocal microscope at 630×. AT1, angiotensin II type 1; 
E2, 17β-oestradiol; EGFR, epidermal growth factor receptor; siRNA, small interfering RNA.Breast Cancer Research    Vol 8 No 3    Lim et al.
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Rapid estrogen signalling is dependent on tyrosine 
kinase receptors
It has been reported that oestrogen transactivates the EGFR
to initiate the MAPK cascade. To examine the role of tyrosine
k i n a s e  r e ce p t o r  E G FR  i n  m e d i at i n g  1 7 β-oestradiol-induced
cell proliferation and MAPK activation in ER-positive and ER-
negative breast cancer cells, we inhibited EGFR with the spe-
cific inhibitor AG1478. 17β-Oestradiol and EGF induced cell
proliferation was attenuated in the presence of AG1478 (Fig-
ure 2a). The EGFR antagonist also diminished steroid and
growth factor induced Raf phosphorylation in both SKBR3
and MCF-7 breast cancer cell lines (Figure 2b).
Oestrogen can signal through G proteins in ER-positive 
and ER-negative breast cancer cell lines
It has been suggested that oestrogens can activate either
membrane-bound ER or GPCR to initiate rapid cell signalling
events. We examined the role of G proteins in 17β-oestradiol
and EGF-induced cell phosphorylation and activation of the
MAPK pathway, in ER-positive and ER-negative cell lines. The
G protein antagonist pertussis toxin inhibited 17β-oestradiol
cell growth and Raf phosphorylation in both ER-positive and
ER-negative cell lines (Figure 3a, b). Of interest, treatment with
pertussis toxin also abrogated the cell growth and Raf phos-
phorylation seen in the presence of EGF and EGF in combina-
tion with 17β-oestradiol, in particular in ER-positive MCF-7
breast cancer cells (Figure 3a, b). We assessed the ability of
17β-oestradiol and EGF to induce the classic GPCR second
messenger cAMP. In SKBR3 cells, levels of cAMP were
increased in the presence of 17β-oestradiol and in the pres-
ence of 17β-oestradiol in combination with EGF (Figure 3c).
Oestrogens can signal through the angiotensin II 
receptor AT1 in human breast cancer cells
A role for the GPCR AT1 was assessed in ER-positive and ER-
negative breast cancer cells. Treatment with the AT1 receptor
antagonist saralasin resulted in attenuation of 17β-oestradiol
and EGF induced cell proliferation in the ER-negative SKBR3
cells and, to a lesser extent, in the ER-positive MCF-7 cells
(Figure 4a). In the SKBR3 cells saralasin inhibited 17β-oestra-
diol induced phosphorylation of Raf (Figure 4b). To investigate
further the role of the AT1 receptor, we knocked down AT1
using siRNA technology. Two predesigned siRNA sequences
targeting AT1 (AT1 #1 and AT1 #2) were assessed for their
ability to knock down AT1 protein expression, compared with
siRNA sequences targeting GAPDH and scrambled siRNA.
AT1 #2 siRNA was found to be more effective at downregu-
lating AT1 protein expression and was therefore used in sub-
sequent experiments (Figure 4c). The ability of 17β-oestradiol
to induce Raf phosphorylation in SKBR3 cells was attenuated
in cells transfected with AT1 #2 siRNA compared with scram-
bled control (Figure 4c).
In paraffin-embedded breast cancer tissue AT1 protein was
found to be expressed predominantly in breast tumour epithe-
lial cells, with little staining detected in the surrounding stromal
cells (Figure 4d). In order to determine cellular localization of
AT1 we performed confocal microscopy. AT1 was found to be
expressed predominantly at the cellular membrane in tumour
epithelial cells of breast cancer tissue and in the SKBR3
breast cancer cell line (Figure 4e).
Discussion
The ability of oestrogen to transactivate EGFRs rapidly in a G-
coupled protein dependent manner has now been estab-
lished. The mechanism of this 'nongenomic' oestrogen signal-
ling and its dependence on a membrane-bound ER, however,
remains controversial. Studies have shown that membrane ER
is similar if not identical to nuclear ER [16], which is linked to
G proteins, activating several second messenger systems
[29]. Investigations using ER-negative cell lines have demon-
strated that oestrogen may also function through ER-inde-
pendent mechanisms. GPCRs, and in particular GPR30, the
orphan GPCR, have been implicated in mediating this ER-
independent oestrogen signalling [21,22]. In this study we
examined rapid oestrogen signalling in ER-positive and ER-
negative, breast cancer cell lines and primary breast cancer
cells derived from patient tumours and investigated a role for
the GPCR AT1 in mediating this effect.
Nongenomic actions of oestrogen result in an array of down-
stream signalling events, which are thought to be largely cell
specific. In breast cancer, rapid oestrogen events have been
shown to include accumulation of cAMP, ERK1/2 and c-fos
[22,30]. In these studies 17β-oestradiol and EGF induced
increased cell proliferation in both ER-positive MCF-7 and ER-
negative SKBR3 breast cancer cell lines. We examined the
ability of 17β-oestradiol and EGF alone and in combination to
activate the MAPK cascade. In breast cancer cell lines and in
primary breast tumour cell cultures, expression of ER was not
required for 17β-oestradiol induced phosphorylation of Raf.
Furthermore, in line with other investigators who have
described activation of ERK1/2 in ER-negative cells [21], we
found that 17β-oestradiol induced ERK1/2 phosphorylation
and translocation from the cytosol to the nucleus in SKBR3
cells. The ability of oestrogens to initiate the MAPK cascade
has been linked to Gβγ protein dependent release of surface
associated heparin-binding EGF, resulting in transactivation of
the EGFR [21,23]. Here, requirement of EGFR transactivation
for maximal oestrogen-mediated cell proliferation and MAPK
activation was established using the receptor EGF inhibitor
AG1478.
Both ER-dependent and ER-independent transactivation of
EGFR has been shown to signal via G coupled proteins, with
several different G protein heterodimers coupling with the
same receptor. Membrane ER can co-immunoprecipitate with
Gs and Gq proteins in transfected and endogenous ER cell
models [16,19], and in ER-negative cells oestrogen-GPR30
dependent activation of MAPK is sensitive to the Gi/o-proteinAvailable online http://breast-cancer-research.com/content/8/3/R33
Page 9 of 10
(page number not for citation purposes)
inhibitor pertussis toxin [22]. Here, pertussis toxin attenuated
17β-oestradiol induced cell proliferation and Raf phosphoryla-
tion in both ER-positive and ER-negative breast cancer cell
lines. Of interest, pertussis toxin also attenuated EGF-induced
breast cancer cell proliferation and phospho-Raf expression.
These observations are consistent with those of other investi-
gators that have observed pertussis toxin induced reductions
in growth factor mediated ERK1/2 activation [31,32]. It has
been proposed that these effects may be mediated via pertus-
sis toxin induced disinhibition of cAMP [31]. To assess further
the role of G coupled proteins we evaluated the accumulation
of the GPCR second messenger cAMP, in response to both
17β-oestradiol and EGF. As previously reported 17β-oestra-
diol induced cAMP levels in ER negative SKBR3 breast can-
cer cells [23]. Although EGF alone had no effect on cAMP
accumulation, EGF synergistically increased oestrogen-
induced cAMP, providing further evidence of crosstalk
between tyrosine kinase receptors and G proteins.
Mediation of the nongenomic effects of oestrogens are likely
to occur in a cell-specific manner, with more than one GPCR
participating in rapid oestrogen signalling. In addition to
GPR30, the membrane bound sex hormone binding globulin
receptor can mediate oestrogen-induced activation of ade-
nylate cyclase via the Gs protein subunit. The angiotensin II
receptor AT1 is another attractive oestrogen-signalling GPCR
candidate. AT1 is a Gq/i coupled receptor, which can lead to
tyrosine kinase phosphorylation, increased phospholipase C
[25,26] and Raf-ERK1/2 activation, which can be partially
inhibited by pertussis toxin [33]. Expression of AT1 in normal
and diseased breast tissue has previously been reported [24].
In the present study immunohistochemistry performed on pri-
mary breast cancer tissue revealed AT1 receptor staining pri-
marily in breast tumour epithelial cells. At a cellular level AT1
was found to be predominantly expressed in the membrane of
tumour epithelial cells and ER-negative breast cancer cell
lines. Here, we investigated the role of the AT1 in mediating
the nongenomic effects of oestrogens in ER-positive and ER-
negative breast cancer cells. The angiotensin II receptor com-
petitive inhibitor saralasin attenuated the proliferative effects of
17β-oestradiol and EGF in SKBR3 and MCF-7 breast cancer
cells, in a similar manner to that seen for pertussis toxin. Of
interest, the inhibitory effects of saralasin were found to be
greater in the ER-negative cells than in ER-positive cells,
which is consistent with the proposed cell specific nature of
nongenomic estrogen signalling. Furthermore, 17β-oestradiol
mediated Raf phosphorylation was inhibited in the presence of
saralasin in SKBR3 cells. To confirm a role for AT1 in nong-
enomic oestrogen signalling in ER-negative cells, we knocked
down AT1 expression with siRNA. Downregulation of AT1 also
attenuated 17β-oestradiol induction of phospho-Raf in the ER-
negative SKBR3 cells.
Conclusion
The mechanisms by which oestrogen couples to G proteins to
mediate its nongenomic effects are likely to be varied and cell
context specific. The data presented here indicate that estro-
gens can activate early cell survival signalling in an ER-inde-
pendent manner not only in ER-negative cell lines but also in
primary breast cultures. We propose that this ER-independent
oestrogen signalling is mediated, at least in part, through the
GPCR AT1. These data suggest that in a clinical setting aro-
matase inhibitors may be beneficial in treating ER-negative as
well as ER-positive breast tumours. Elucidation of the compo-
nents of the nongenomic oestrogen signalling cascade will
provide important information regarding the role of oestrogens
in physiological and pathophysiological conditions.
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